Table of Contents
<< Previous Issue | Mar 2023 (Vol: 2023, Issue: 3) | Next Issue >> |
- Section: Licensing
-
Eli Lilly Licenses Non-Opioid Pain Drug from Confo Therapeutics
-
ImmunoGen Signs Partnership with Vertex for Conditioning Agents worth US$352 M
- Section: Mergers & Acquisitions
-
Pfizer to Acquire ADC Cancer Specialist Seagen for US$43 B
-
Sanofi Buys Provention Bio and its Type 1 Diabetes Drug for US$2.9 B
-
Adaptimmune and TCR2 Merge to Form a Solid Tumour Company
- Section: Opinion & Analysis
-
IQVIA Pharma Deals Review of 2022
- Section: Research & Development
-
Merck Signs US$922.5 M Collaboration with OPKO Health for Epstein-Barr Virus Vaccine
-
BioNTech Collaborates with OncoC4 to Co-Develop CTLA-4 Cancer Antibody
-
UCB Enters into Drug Discovery Collaboration with Aitia for Huntington’s Disease